NR4A1 and cancer: Although progesterone receptor (PR) was assessed for invasive and not DCIS cases, it was uncommon for invasive breast cancer in the CBCS to be PR positive and ER negative and therefore differentiation between subgroups of hormone receptor positive cancers was not possible.